- Home
- STTK vs ACHV Comparison
STTK vs ACHV Comparison
Compare STTK & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- ACHV
- Stock Information
- Founded
- STTK 2016
- ACHV N/A
- Country
- STTK United States
- ACHV Canada
- Employees
- STTK N/A
- ACHV N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- STTK Health Care
- ACHV Health Care
- Exchange
- STTK Nasdaq
- ACHV Nasdaq
- Market Cap
- STTK 173.6M
- ACHV 159.0M
- IPO Year
- STTK 2020
- ACHV N/A
- Fundamental
- Price
- STTK $3.76
- ACHV $4.47
- Analyst Decision
- STTK Strong Buy
- ACHV Strong Buy
- Analyst Count
- STTK 3
- ACHV 3
- Target Price
- STTK $10.67
- ACHV $14.00
- AVG Volume (30 Days)
- STTK 123.5K
- ACHV 87.7K
- Earning Date
- STTK 11-07-2024
- ACHV 11-07-2024
- Dividend Yield
- STTK N/A
- ACHV N/A
- EPS Growth
- STTK N/A
- ACHV N/A
- EPS
- STTK N/A
- ACHV N/A
- Revenue
- STTK $4,123,999.00
- ACHV N/A
- Revenue This Year
- STTK $164.45
- ACHV N/A
- Revenue Next Year
- STTK N/A
- ACHV N/A
- P/E Ratio
- STTK N/A
- ACHV N/A
- Revenue Growth
- STTK 380.09
- ACHV N/A
- 52 Week Low
- STTK $1.33
- ACHV $3.03
- 52 Week High
- STTK $11.76
- ACHV $5.98
- Technical
- Relative Strength Index (RSI)
- STTK 53.48
- ACHV 51.93
- Support Level
- STTK $3.63
- ACHV $4.23
- Resistance Level
- STTK $3.94
- ACHV $4.64
- Average True Range (ATR)
- STTK 0.23
- ACHV 0.16
- MACD
- STTK 0.05
- ACHV 0.03
- Stochastic Oscillator
- STTK 68.42
- ACHV 69.43
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.